combination therapy

Research in Review

Triplet Combination Shows Long-Term Efficacy in Advanced Multiple Myeloma

06/26/2017

JCP Editors

Combination therapy involving a novel treatment is associated with reduced risk of death and improved progression-free survival (PFS) in patients with advanced multiple myeloma, according to research presented at the...

...

06/26/2017

Journal of Clinical Pathways

Research in Review

Adding Targeted Therapy Improves CAR-T Response Rates in CLL

06/15/2017

JCP Editors

Researchers report significantly improved response rates in patients with chronic lymphocytic leukemia (CLL) treated with concurrent targeted therapy and chimeric antigen receptor T-cell (CAR-T)...

...

06/15/2017

Journal of Clinical Pathways

Research in Review

Brain Metastases Resistant to Targeted Therapy Due to Gene Overexpression

06/14/2017

JCP Editors

A novel mechanism responsible for brain metastasis resistance to targeted therapy has been identified, which may help guide treatment strategies, according to a study published in Science Translational Medicine...

A...

06/14/2017

Journal of Clinical Pathways

Research in Review

Combination Therapy Improves Outcomes for Patients With MCL

06/08/2017

JCP Editors

Patients with mantle cell lymphoma (MCL) have increased odds of achieving complete remission after being treated with a combination regimen, according to research presented at the 2017 ASCO Annual Meeting (June 2-6,...

...

06/08/2017

Journal of Clinical Pathways

Research in Review

Metastatic Hormone-Na√Øve Prostate Cancer Effectively Treated With Combination Therapy

06/07/2017

JCP Editors

Groundbreaking results of a trial have shown that the combination of a new drug with androgen deprivation therapy (ADT) significantly improves overall survival (OS) and radiographic progression-free survival (PFS) in...

...

06/07/2017

Journal of Clinical Pathways

Research in Review

Triple Combination Active in High-Risk B-Cell Malignancies

05/24/2017

JCP Editors

A combination of 3 pathway inhibitors is well tolerated with activity observed in heavily pre-treated and high-risk B-cell malignancies, according to research that will be presented at the ASCO Annual Meeting (June...

A...

05/24/2017

Journal of Clinical Pathways

Research in Review

Lenalidomide Maintenance Prolongs PFS in Older Patients With Diffuse B-Cell Lymphoma

05/12/2017

JCP Editors

Lenalidomide maintenance therapy for 24 months after obtaining a complete or partial response to standard chemotherapy significantly prolongs progression-free survival (PFS) in older patients with diffuse large...

...

05/12/2017

Journal of Clinical Pathways

Research in Review

Combination Therapy Effective in Treating Chemo-Resistant Ovarian Cancer

05/09/2017

JCP Editors

A combination regimen involving standard carboplatin chemotherapy and a novel drug may improve overall survival for more than 50% of women with high-grade serous ovarian cancers, according to research published in...

A...

05/09/2017

Journal of Clinical Pathways

Research in Review

Lenalidomide Maintenance Prolongs PFS in Older Patients With Diffuse Large B-Cell Lymphoma

04/28/2017

JCP Editors

Lenalidomide maintenance therapy for 24 months after a complete or partial response to standard chemotherapy significantly prolongs progression-free survival (PFS) in older patients with diffuse large B-cell...

...

04/28/2017

Journal of Clinical Pathways

Research in Review

Palbociclib Plus Fulvestrant Improves PFS in Type of Breast Cancer

04/19/2017

JCP Editors

Adding palbociclib to fulvestrant prolongs progression-free survival (PFS) compared with fulvestrant alone among pre- and post-menopausal women with hormone receptor (HR)-positive, human epidermal growth factor...

Adding...

04/19/2017

Journal of Clinical Pathways